Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Bunkyō City
Clinical trial register · Japan

Clinical Trials in Bunkyō City, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca61 Janssen Research & Development, LLC26 Eli Lilly and Company20 Alexion Pharmaceuticals, Inc.6 Gilead Sciences4
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Bunkyō City

169 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Not yet open
A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)
NCT07843459Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
Eli Lilly and Company
Phase 1
111
Bunkyō City, Ōbu
2026-10
Recruiting
Eli Lilly and Company
Phase 1
179
Bunkyō City, Ōbu
2026-09-09
Recruiting
Incyte Corporation
Phase 3
426
Bunkyō City, Chūō, Fukuoka, Fukushima, Hirakata, Kagoshima, Kashiwa-shi, Kobe
2026-09-08
Not yet open
A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
NCT07787182Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
DrugLY4405094
Eli Lilly and Company
Phase 1
68
Bunkyō City, Ōbu
2026-09
Recruiting
Sun Pharma Japan Limited
Phase 3
78
Asahikawa, Bunkyō City, Ebina, Hamamatsu, Ishikawa, Kitakyushu, Kōtoku, Kurashiki
2026-06-19
Active, closed
AstraZeneca
Phase 2
326
Bunkyō City, Kurume-shi, Sapporo, Shinjuku-ku, Suita
2026-06-11
Recruiting
Dompé Farmaceutici S.p.A
Phase 3
150
Tōon, Bunkyō City
2026-06-02
Recruiting
Janssen Research & Development, LLC
Phase 3
644
Bunkyō City, Hamamatsu, Higashi-Ibaraki, Kagoshima, Kashiwa, Kumamoto, Minatoku, Mitaka
2026-05-23
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Bunkyō City, Hamamatsu, Hirosaki, Kagoshima, Kashiwa, Kobe, Kumamoto, Minatoku
2026-05-22
Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
DrugDonanemab
Eli Lilly and Company
Phase 2
350
Bunkyō City, Fujisawa, Himeji, Inage, Kawasaki, Kobe, Kōtoku, Kurashiki
2026-05-20
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Asahikawa, Bunkyō City, Fujiidera, Fukuoka, Hirosaki, Kagoshima, Kashiwa, Mitaka
2026-03-26
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Aichi, Bunkyō City, Chiba, Chūō, Fuchū, Fukuoka, Fukushima, Isehara
2026-03-05
Recruiting
AstraZeneca
Phase 3
508
Bunkyō City, Kashiwa, Kyoto, Nagoya, Shibuya-ku, Shinjuku-ku
2026-02-23
Recruiting
Eli Lilly and Company
Phase 3
800
Bunkyō City, Fukuoka, Kitahiroshima, Kitakyushu, Minatoku, Osaka, Sapporo, Shibuya-ku
2026-02-10
Recruiting
Janssen Research & Development, LLC
Phase 3
400
Bunkyō City, Chiba, Kamakura-shi, Kamogawa, Kofu, Minato, Shibuya City, Yokohama
2026-02-04
Recruiting
AstraZeneca
Phase 3
2,130
Bunkyō City, Chūōku, Hirakata-shi, Hiroshima, Kashiwa, Kitaadachi-gun, Kōtoku, Kurashiki-shi
2026-02-03
Recruiting
Sanofi
Phase 3
751
Bunkyō City, Chikushino-shi, Hachiōji, Kagoshima, Kamakura, Kashiwa, Kobe, Kōriyama
2026-01-16
Recruiting
AstraZeneca
Phase 1/2
84
Bunkyō City, Kashiwa, Okayama
2026-01-09
Recruiting
Alnylam Pharmaceuticals
Observational
2,000
Bunkyō City, Kumamoto, Kurume, Matsumoto, Sendai, Shinjuku, Suita, Tsukuba
2026-01-09
Recruiting
Eli Lilly and Company
Phase 3
800
Bunkyō City, Chiba, Fukuoka, Fukushima, Hidaka, Hirakata, Hiroshima, Kagoshima
2025-12-22
Recruiting
Janssen Research & Development, LLC
Phase 3
800
Bunkyō City, Hirakata, Kanazawa, Kobe, Sagamihara, Sunto Gun, Yokohama
2025-12-19
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 4
20
Bunkyō City, Hirakata-shi, Iruma-Gun, Kyoto, Matsumoto-shi, Miyazaki, Nagoya, Nara
2025-12-19
Recruiting
AstraZeneca
Phase 2
320
Aomori, Bunkyō City, Fukuoka, Hamamatsu, Hitachi-Naka, Iizuka-shi, Kawachinagano-shi, Matsuyama
2025-12-15
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer
DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed
AstraZeneca
Phase 1/2
152
Bunkyō City, Kashiwa, Kurume-shi, Kyoto, Niigata, Shinjuku-ku, Toyoake-shi
2025-11-24
Recruiting
AstraZeneca
Phase 1/2
83
Bunkyō City, Chūōku, Kashiwa
2025-11-12
Recruiting
AstraZeneca
Phase 3
420
Akashi, Bunkyō City, Himeji-shi, Kōtoku, Kumamoto, Matsumoto-shi, Matsuyama, Meguro-ku
2025-11-11
Recruiting
AstraZeneca
Phase 2
435
Bunkyō City, Gifu, Hiratsuka-shi, Kamogawa-shi, Kiyose-shi, Kurashiki-shi, Meguro-ku, Miyazaki
2025-11-06
Recruiting
BioNTech SE
Phase 3
558
Bunkyō City, Chiba, Fukushima, Gifu, Hidaka, Hiroshima, Kagoshima, Kōtoku
2025-10-30
Recruiting
Eli Lilly and Company
Phase 3
4,500
Amagasaki, Asahikawa, Bunkyō, Bunkyō City, Chikushino-shi, Fukuoka, Gifu, Ginowan
2025-10-15
Recruiting
Sanofi
Phase 3
980
Asahikawa, Bunkyō City, Chikushino-shi, Chūō, Fukuoka, Kagoshima, Kamakura, Kanazawa
2025-10-08
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 4
200
Bunkyō City, Kumamoto, Kurume-shi, Kyoto, Mitaka-shi, Nagoya, Nankoku-shi, Okayama
2025-10-01
Recruiting
Sanofi
Phase 3
980
Shizuoka, Asahikawa, Bunkyō City, Chikushino-shi, Fukuoka, Hachiōji, Isehara, Isesaki
2025-10-01
Recruiting
Daiichi Sankyo
Phase 2/3
630
Bunkyō City, Fukuoka, Hirosaki-shi, Kanazawa, Kawasaki, Kōtoku, Kumamoto, Kyoto
2025-09-26
Recruiting
AstraZeneca
Phase 1/2
91
Bunkyō City, Kōtoku
2025-09-24
Recruiting
Janssen Research & Development, LLC
Phase 3
220
Bunkyō City, Funabashi Shi, Hakodate, Kawasaki, Minatoku, Sakura, Yokohama
2025-09-10
Recruiting
Alnylam Pharmaceuticals
Phase 3
11,000
Bunkyō City, Chikushino-shi, Chūōku, Fukuoka, Hachioji-Shi, Hachiōji, Hakodate-Shi, Hakusan
2025-09-06
Recruiting
Janssen Research & Development, LLC
Phase 3
1,203
Bunkyō City, Fukuoka, Gifu, Hidaka, Kanazawa, Kashiwa, Kobe, Matsuyama
2025-09-02
Recruiting
Eli Lilly and Company
Phase 3
3,400
Bunkyō City, Tokyo
2025-08-25
Recruiting
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
DrugsEmpasiprubart·IVIG
argenx
Phase 3
218
Aomori, Bunkyō City, Chūōku, Hiroshima, Izunokuni, Osaka, Saga, Shimotsuke
2025-08-22
Recruiting
AstraZeneca
Phase 2
278
Bunkyō City, Fukuyama-shi, Kobe, Kurume-shi, Kyoto, Osaka, Sakaishi, Shinjuku-ku
2025-08-07
Recruiting
AstraZeneca
Phase 3
700
Bunkyō City, Fukuoka, Kamakura-shi, Kawagoe-shi, Kawasaki-shi, Kisarazu-shi, Kumamoto, Kyoto
2025-08-06
Recruiting
Alnylam Pharmaceuticals
Phase 3
1,750
Bunkyō City, Fukuoka, Kagawa, Kashihara, Kobe, Kumamoto, Kurume, Matsumoto-shi
2025-07-02
Recruiting
AstraZeneca
Phase 3
15,100
Ami-machi, Asahi-shi, Asahikawa-shi, Bunkyō City, Chiyoda-ku, Chūōku, Fujisawa-shi, Fukui-shi
2025-06-04
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Bunkyō City, Fukuoka, Fukushima, Gifu, Kanazawa, Kobe, Kumamoto, Maebashi
2025-06-04
Recruiting
Sanofi
Phase 2
99
Kashiwa, Ōita, Hamamatsu, Bunkyō City, Hirosaki, Morioka, Nishinomiya
2025-06-03
Recruiting
AstraZeneca
Phase 3
1,220
Bunkyō City, Chiba, Fukuoka, Hiroshima, Iizuka-shi, Kashiwa, Kita-gun, Kobe
2025-05-06
Recruiting
AstraZeneca
Phase 1
72
Bunkyō City, Kita-gun, Kitakyushu-shi, Kyoto, Nagasaki
2025-05-01
Recruiting
AstraZeneca
Phase 3
830
Akashi, Bunkyō City, Fukuoka, Hamamatsu, Iwakuni-shi, Izumi-shi, Kashihara-shi, Kobe
2025-04-10
Recruiting
Eli Lilly and Company
Phase 3
700
Bunkyō City, Fukuoka, Hidaka, Himeji, Hirakata, Kanazawa, Kashiwa, Kōtō City
2025-03-27
Recruiting
AstraZeneca
Phase 3
840
Akashi-shi, Bunkyō City, Chūōku, Fukuoka, Hidaka-shi, Hirakata-shi, Hiroshima, Kasama-shi
2025-03-01
Recruiting
Masahisa Katsuno
Phase 2/3
68
Bunkyō City, Chiba, Sapporo, Shimotsuke, Suita
2025-02-28
Recruiting
Daiichi Sankyo
Phase 3
726
Bunkyō City, Chūōku, Gifu, Hiroshima, Kashiwa-shi, Kitakyushu, Kochi, Kōtoku
2025-02-27
Recruiting
BioNTech SE
Phase 3
621
Ageo, Bunkyō City, Chūōku, Fukuoka, Hidaka, Himeji, Iwakuni, Kobe
2025-02-03
Recruiting
BioNTech SE
Phase 2/3
1,580
Ageo, Akashi, Aomori, Bunkyō City, Chūōku, Funabashi, Himeji, Hiroshima
2025-01-07
Active, closed
argenx
Phase 3
154
Bunkyō City, Chūōku, Kodaira, Nagoya, tabashi City, Ube
2024-12-18
Active, closed
H. Lundbeck A/S
Phase 3
401
Nagoya, Toyoake-Shi, Gifu, Sapporo, Sendai, Niigata, Iruma-shi, Bunkyō City
2024-12-03
Recruiting
AstraZeneca
Phase 3
1,160
Amagasaki-shi, Bunkyō City, Chūōku, Fukuoka, Hiroshima, Kawagoe-shi, Kawasaki-shi, Kitaadachi-gun
2024-11-27
Active, closed
Genmab
Phase 3
191
Matsuyama, Kitakyushu-shi, Hiroshima, Kobe, Kumamoto, Osakasayama-shi, Bunkyō City, Chūōku
2024-11-25
Recruiting
UCB Biopharma SRL
Phase 3
450
Bunkyō City, Chūōku, Fukuoka, Kawagoe, Kawasaki-shi, Kita-gun, Kitakyushu, Kurashiki
2024-11-21
Active, closed
Daiichi Sankyo
Phase 3
700
Akita, Aomori, Bunkyō City, Chiba, Fukuoka, Fukuyama, Gifu, Hamamatsu
2024-11-19
Recruiting
AstraZeneca
Phase 3
1,160
Amagasaki-shi, Bunkyō City, Chūōku, Fukuoka, Hirakata-shi, Hiroshima, Kakogawa-shi, Kanazawa
2024-11-18
Recruiting
Boehringer Ingelheim
Phase 3
1,590
Bunkyō City, Chiba, Ehime, Toon, Fukui-shi, Fukuoka, Fukuoka, Fukuoka, Kurume, Gifu, Gifu, Gifu, Ogaki
2024-11-12
Recruiting
Eli Lilly and Company
Phase 1
128
Bunkyō City, Ōbu
2024-10-29
Active, closed
Eli Lilly and Company
Phase 3
1,400
Bunkyō City, Chūōku, Fujisawa, Fukuoka, Hachiōji, Himeji, Imabari, Kobe
2024-10-24
Active, closed
AstraZeneca
Phase 3
25
Bunkyō City, Chiba, Chūōku, Fukuoka, Hidaka-shi, Hiroshima, Iwakuni-shi, Kashiwa
2024-10-15
Recruiting
Boehringer Ingelheim
Phase 3
1,800
Bunkyō City, Chiba, Chiba, Ichikawa, Ehime, Toon, Fukui-shi, Fukuoka, Fukuoka, Fukuoka, Kurume, Gifu, Gifu
2024-10-14
Active, closed
Incyte Corporation
Phase 3
346
Bunkyō City, Inashiki-gun, Kamimashiki-gun, Kawasaki-shi, Kitakyushu, Kobe, Kumamoto, Minamikoshigaya
2024-10-10
Active, closed
AstraZeneca
Phase 3
768
Bunkyō City, Fukuoka, Hiroshima, Iruma-Gun, Iwakuni-shi, Kobe, Kōtoku, Kumamoto
2024-10-04
Active, closed
Zenas BioPharma (USA), LLC
Phase 2
190
Nagoya, Kitakyushu-shi, Naha, Kita-ku, Bunkyō City
2024-09-17
Recruiting
Gossamer Bio USA, Inc.
Phase 3
330
Bunkyō City, Fukuoka, Mitaka, Nagoya, Okayama, Shinjuku-Ku, Suita
2024-09-03
Active, closed
Ferring Pharmaceuticals
Observational
1,526
Chiba, Fukuoka, Kitakyushu, Takasaki, Hiroshima, Bunkyō City, Tokyo, Hokkaido
2024-08-27
Recruiting
Eli Lilly and Company
Phase 1
48
Bunkyō City
2024-08-15
Recruiting
AstraZeneca
Phase 3
620
Bunkyō City, Chiba, Fukuyama-shi, Hirakata-shi, Hiroshima, Kanazawa, Kashiwa, Kawasaki-shi
2024-08-12
Recruiting
AstraZeneca
Phase 3
1,018
Bunkyō City, Chiba, Chuo-shi, Fukuoka, Hirakata-shi, Kobe, Kōtoku, Kumamoto
2024-08-07
Recruiting
ARCAGY/ GINECO GROUP
Phase 3
250
Bunkyō City, Fukushima, Hidaka, Hirosaki, Kashiwa, Kawasaki, Koshigaya, Kurume
2024-07-30
Recruiting
AstraZeneca
Phase 3
240
Asahikawa-Shi, Bunkyō City, Chiba, Fukuoka, Hiroshima, Iruma-Gun, Kawachinagano-shi, Kawasaki-shi
2024-06-20
Recruiting
AstraZeneca
Phase 3
3,850
Beppu-shi, Bunkyō City, Fujisawa-shi, Fukui-shi, Fukuoka, Fukutsu-shi, Hakusan-shi, Higashiibaraki-gun
2024-04-12
Recruiting
AstraZeneca
Phase 3
675
Bunkyō City, Fukuoka, Hakodate-shi, Hidaka-shi, Hirakata-shi, Hirosaki-shi, Hiroshima, Kanazawa
2024-04-11
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
43
Bunkyō City, Minatoku, Suita-shi, Yonago-shi
2024-04-02
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
584
Bunkyō City, Chiba, Fukuoka, Kamakura, Kasugai-shi, Kitakyushu-shi, Kobe, Matsumoto-shi
2024-03-29
Recruiting
AstraZeneca
Phase 3
100
Bunkyō City, Chiba, Fuchu-shi, Kawasaki-shi, Kobe, Nagasaki, Obu-shi, Shinjuku-ku
2024-03-14
Recruiting
Eli Lilly and Company
Phase 3
90
Bunkyō City, Hirosaki, Kagoshima, Kashiwa-shi, Kobe, Saga, Sendai, Setagaya-ku
2024-03-13
Recruiting
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
NCT06137144Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)
DrugsAZD3470·Keytruda·Pembrolizumab
AstraZeneca
Phase 1/2
161
Bunkyō City, Kōtoku
2024-01-23
Active, closed
Janssen Research & Development, LLC
Phase 3
838
Bunkyō City, Fukuoka, Hamamatsu, Kanazawa, Kyoto, Nagasaki, Narita, Niigata
2024-01-22
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,181
Bunkyō City, Kumamoto, Kurume-shi, Kyoto, Matsumoto-shi, Sapporo, Shinjuku-ku, Suita-shi
2024-01-11
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Bunkyō City, Chiba, Chūōku, Fukuoka, Kashiwa, Kyoto, Okayama, Osaka
2023-12-29
Recruiting
Eli Lilly and Company
Phase 3
1,264
Asahikawa, Bunkyō City, Fukuoka, Hidaka, Himeji, Hirakata, Kanazawa, Kasama
2023-12-21
Recruiting
Janssen Research & Development, LLC
Phase 1
300
Bunkyō City, Kashiwa
2023-12-20
Recruiting
AstraZeneca
Phase 3
1,145
Bunkyō City, Chiba, Chūōku, Fukuoka, Hidaka-shi, Hiroshima, Kashiwa, Kobe
2023-12-14
Recruiting
AstraZeneca
Phase 3
625
Akashi-shi, Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Gifu, Hidaka-shi
2023-11-23
Active, closed
AstraZeneca
Phase 3
1,902
Akashi-shi, Akita, Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Gifu
2023-11-14
Active, closed
AstraZeneca
Phase 3
314
Bunkyō City, Fukuoka, Iruma-Gun, Kanazawa, Maebashi, Nagasaki, Nagoya, Sapporo
2023-11-08
Active, closed
AstraZeneca
Phase 3
895
Bunkyō City, Fukuoka, Kashiwa, Kawasaki-shi, Kōtoku, Matsuyama, Nagoya, Okayama
2023-10-24
Active, closed
Stichting European Myeloma Network
Phase 3
759
Bunkyō City, Fukuoka, Hokkaido, Hyōgo, Kanazawa, Nagoya, Okayama, Osaka
2023-10-10
Active, closed
AstraZeneca
Phase 3
5,511
Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Hirakata-shi, Hiroshima, Iruma-Gun
2023-10-05
By invitation
argenx
Phase 3
240
Bunkyō City, Nagoya, Tokyo, Wakayama, Yamaguchi
2023-09-12
Active, closed
Gilead Sciences
Phase 3
654
Aichi, Aoba-ku, Bunkyō City, Chiba, Chūōku, Ehime, Fukushima, Kagoshima
2023-05-08
Active, closed
Janssen Research & Development, LLC
Phase 3
20,284
Aichi, Bunkyō City, Chiba, Chikushino-shi, Fukuoka, Funabashi-shi, Gifu, Higashiibaraki-gun
2023-04-11
Active, closed
Janssen Research & Development, LLC
Phase 3
614
Bunkyō City, Chiba, Gifu, Gunma, Hirakata, Hitachi, Iruma-gun, Kamogawa
2023-03-29
Active, closed
AstraZeneca
Phase 3
1,350
Bunkyō City, Chūōku, Hamamatsu, Hidaka-shi, Hirosaki-shi, Hiroshima, Kumamoto, Nagoya
2022-12-29
Active, closed
Viatris Innovation GmbH
Phase 3
470
Amagasaki-shi, Bunkyō City, Chiba, Chuo-shi, Chūōku, Fukuoka, Hiroshima, Hitachi-Naka
2022-12-13
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
80
Bunkyō City, Kyoto, Osaka, Shibuya-ku, Tsukuba
2022-10-28
Recruiting
Janssen Research & Development, LLC
Phase 3
1,590
Bunkyō City, Chiba, Higashiibaraki-gun, Hirakata, Hyôgo, Iruma-gun, Kanagawa, Kanazawa
2022-10-25
Active, closed
Janssen Research & Development, LLC
Phase 3
864
Bunkyō City, Chiba, Fukuoka, Gifu, Gunma, Hirakata, Hyōgo, Kamakura-shi
2022-10-13
Active, closed
Eli Lilly and Company
Phase 3
8,000
Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Fukuyama, Gifu, Hachioji-shi
2022-10-04
Recruiting
Janssen Research & Development, LLC
Phase 2/3
201
Asahikawa, Bunkyō City, Chiba, Hamamatsu, Isehara, Kobe, Kodaira-shi, Koshigaya
2022-09-23
Active, closed
Janssen Research & Development, LLC
Phase 2
577
Asahikawa, Bunkyō City, Chikushino-shi, Fukuoka-ken, Gifu, Hachiōji, Hamamatsu, Hirosaki
2022-09-19
Active, closed
AstraZeneca
Phase 3
594
Bunkyō City, Chūōku, Kōtoku, Kurashiki-shi, Kurume-shi, Matsuyama, Nagoya, Niigata
2022-09-15
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Bunkyō City, Chūōku, Fujiidera-shi, Fukuoka, Fukushima, Hachinohe, Hachiōji, Hamamatsu
2022-09-13
Active, closed
AstraZeneca
Phase 3
341
Bunkyō City, Chūōku, Fukuoka, Hirosaki-shi, Hiroshima, Iwakuni-shi, Kanazawa, Kashiwa
2022-08-03
Active, closed
Gilead Sciences
Phase 3
443
Aichi, Aoba-ku, Bunkyō City, Chūōku, Ehime, Fukushima, Inamachi, Kagoshima
2022-07-25
Active, closed
Janssen Research & Development, LLC
Phase 2
703
Asahikawa, Bunkyō City, Chikushino-shi, Fukuoka, Hachiōji, Hamamatsu, Hirosaki, Hitachi
2022-07-22
Active, closed
Gilead Sciences
Phase 3
623
Aichi, Bunkyō City, Chūōku, Ehime, Kagoshima, Kashiwa, Kōtoku, Kumamoto
2022-07-20
By invitation
AstraZeneca
Phase 3
214
Bunkyō City, Fukuoka, Kanazawa, Kōtoku, Nagoya, Okayama, Saga, Sunto-gun
2022-04-19
Active, closed
COMBINE-INTERVENE: COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events
NCT05333068Multivessel Coronary Artery Disease, Ischemia, Vulnerable Plaque, Coronary Artery Disease
Diagram B.V.
Not applicable
1,223
Bunkyō City, Yokohama
2022-03-16
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
DrugsAzoles·Gilteritinib·Azacitidine·Venetoclax
Sumitomo Pharma America, Inc.
Phase 1/2
606
Kashiwa-shi, Yoshida-gun, Fukushima, Isehara-shi, Nagasaki, Bunkyo-ku, Bunkyō City, Fukuoka
2022-02-28
Active, closed
AstraZeneca
Phase 3
791
Bunkyō City, Chiba, Fukuoka, Hidaka-shi, Hirosaki-shi, Itabashi-ku, Kashihara-shi, Kōtoku
2022-02-18
Active, closed
AstraZeneca
Phase 3
363
Bunkyō City, Chiba, Hiroshima, Kita-gun, Kitakyushu-shi, Matsumoto-shi, Nagasaki, Okayama
2022-02-15
Active, closed
Janssen Research & Development, LLC
Phase 3
350
Bunkyō City, Chūōku, Fukui-ken, Fukuoka, Fukuyama, Gamagōri, Gunma, Hachinohe
2022-01-19
Active, closed
Washington University School of Medicine
Phase 2/3
197
Bunkyō City
2021-12-22
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Bunkyō City, Hiroshima, Kashiwa, Nagoya, Osaka, Osaka Sayama Shi, Sendai, Shimotsuke
2021-12-10
Active, closed
Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors
NCT05101096Advanced Solid Tumor, Metastatic Triple-Negative Breast Cancer, HR+/HER2- Metastatic Breast Cancer, Metastatic Urothelial Cancer
DrugSacituzumab Govitecan
Gilead Sciences
Phase 1/2
135
Aichi, Akita, Aoba-ku, Aomori, Asahi-ku, Bunkyō City, Chiba, Chūōku
2021-10-20
Active, closed
A Long-term Extension Study of Ustekinumab in Pediatric Participants
NCT05092269Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
DrugUstekinumab
Janssen Research & Development, LLC
Phase 3
159
Bunkyō City, Gunma, Ikoma, Kurume, Saitama Shi, Sendai, Setagaya Ku, Tsu
2021-10-18
Active, closed
Loxo Oncology, Inc.
Phase 3
600
Bunkyō City, Chiba-Ken, Chūō, Chūōku, Fukui, Kōtō City, Kyoto, Nankoku
2021-09-20
Active, closed
Eli Lilly and Company
Phase 3
2,996
Bunkyō City, Chūōku, Hachiōji, Osaka, Ōbu, Shinjuku, Shinjuku-ku, Suita-shi
2021-08-27
Active, closed
Janssen Research & Development, LLC
Phase 3
743
Bunkyō City, Fukuoka, Hyôgo, Kanazawa, Kyoto, Nagoya, Okayama, Sapporo
2021-08-19
By invitation
Viatris Innovation GmbH
Phase 3
25,000
Akishima-shi, Amagasaki-shi, Asahi-shi, Bunkyō City, Chiba, Chikushino-shi, Chūō, Daito-shi
2021-08-14
Recruiting
X-linked Moesin Associated Immunodeficiency
NCT06278337Immune Deficiency, Autoimmune Diseases, Infections, Diagnosis
Institut National de la Santé Et de la Recherche Médicale, France
Observational
16
Bunkyō City
2021-08-12
Active, closed
AstraZeneca
Phase 3
712
Bunkyō City, Fukuoka, Hamamatsu, Ichikawa-shi, Kanazawa, Kashihara-shi, Kawasaki-shi, Kita-gun
2021-08-05
Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
150
Bunkyō, Bunkyō City, Kashiwa, Kobe, Tokyo, Yokohama
2021-05-26
Active, closed
Biogen
Phase 3
158
Kagoshima, Bunkyō City
2021-05-17
Active, closed
AstraZeneca
Phase 3
1,157
Akashi-shi, Aomori, Bunkyō City, Chiba, Chūōku, Fukushima, Hidaka-shi, Hiroshima
2021-04-26
Recruiting
UCB Biopharma SRL
Phase 3
70
Bunkyō City, Chūō, Gifu, Hiroshima, Kodaira-shi, Kōshi, Kyoto, Nagoya
2021-03-11
Active, closed
Celgene
Phase 3
313
Nagasaki, Sayama, Bunkyo-ku, Chūō, Aomori, Bunkyō City, Isehara City, Kanagawa, Kamakura
2021-02-25
Active, closed
AstraZeneca
Phase 3
358
Akashi-shi, Bunkyō City, Chiba, Hiroshima, Kashiwa, Kōtoku, Kyoto, Niigata
2020-12-16
Recruiting
Taiho Pharmaceutical Co., Ltd.
Phase 1
59
Bunkyō City, Fukushima, Iruma, Kyoto, Nagasaki, Osaka, Sakai, Shinagawa-Ku
2020-10-30
Active, closed
AstraZeneca
Phase 3
640
Bunkyō City, Chūōku, Hidaka-shi, Hirakata-shi, Hiroshima, Kashiwa, Kitaadachi-gun, Kōtoku
2020-10-19
Active, closed
Janssen Research & Development, LLC
Phase 3
308
Bunkyō City, Hidaka, Himeji, Hirakata, Kanazawa, Kashiwa, Kishiwada, Kobe
2020-10-13
Active, closed
Bristol-Myers Squibb
Phase 1/2
31
Suwa, Bunkyo-ku, Chūō, Aomori, Bunkyō City, Fukuoka, Hitachi, Ibaraki, Isehara City, Kanagawa
2020-10-12
Active, closed
Janssen Research & Development, LLC
Phase 3
1,074
Bunkyō City, Chūōku, Fukuoka, Himeji, Hirakata, Kanazawa, Kashiwa, Kurume
2020-09-30
Active, closed
argenx
Phase 2
229
Bunkyō City, Chiba, Fuchū, Fukuoka, Ginowan, Hakodate, Hiroshima, Kawagoe
2020-09-18
Active, closed
Incyte Corporation
Phase 2
112
Bunkyō City, Chūō, Hirakata, Isehara, Kobe, Kyoto, Matsumoto-shi, Miyagi
2020-08-03
Active, closed
AstraZeneca
Phase 3
866
Akashi-shi, Bunkyō City, Chiba, Chūōku, Fukuoka, Gifu, Hidaka-shi, Hiroshima
2020-07-24
Active, closed
AstraZeneca
Phase 3
1,012
Bunkyō City, Chiba, Chūōku, Fukuoka, Hamamatsu, Hirakata-shi, Hirosaki-shi, Isehara-shi
2020-07-13
Active, closed
Actelion
Phase 3
935
Bunkyō City, Fukuoka, Hiroshima, Kagoshima, Kanagawa, Kanazawa, Kobe, Kurume
2020-06-30
Active, closed
Astellas Pharma Global Development, Inc.
Phase 3
886
Bunkyō City, Chiba, Fukuoka, Hirosaki, Kawasaki-shi, Kōtoku, Kyoto, Niigata
2020-03-30
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,064
Bunkyō City, Chiba, Chikushino-shi, Ehime, Fujiidera-shi, Fukuoka, Fukuoka-ken, Fukushima
2019-09-26
Active, closed
AstraZeneca
Phase 3
587
Bunkyō City, Fukuoka, Hidaka-shi, Himeji-shi, Iwakuni-shi, Kanazawa, Kashiwa, Kōtoku
2019-07-02
Active, closed
AstraZeneca
Phase 3
923
Bunkyō City, Fukuoka, Hidaka-shi, Hiroshima, Kagoshima, Kitaadachi-gun, Kōtoku, Kumamoto
2019-06-25
Recruiting
AstraZeneca
Phase 3
140
Bunkyō City, Fuchu-shi, Fukuoka, Kawasaki-shi, Kobe, Matsumoto-shi, Nakagami-gun, Saitama-Shi
2019-04-02
Active, closed
AstraZeneca
Phase 3
724
Akashi-shi, Bunkyō City, Chūōku, Fukuoka, Hirosaki-shi, Hiroshima, Kobe, Niigata
2019-03-06
Active, closed
AstraZeneca
Phase 3
724
Bunkyō City, Chiba, Chūōku, Fukuoka, Hiroshima, Kurume-shi, Musashino-shi, Nagoya
2018-11-30
Active, closed
AstraZeneca
Phase 3
1,063
Bunkyō City, Fukuoka, Hirosaki-shi, Hiroshima, Kanazawa, Kōtoku, Kumamoto, Miyazaki
2018-11-16
Active, closed
AstraZeneca
Phase 3
895
Bunkyō City, Hirakata-shi, Kanazawa, Kashihara-shi, Kawagoe-shi, Kita-gun, Kyoto, Maebashi
2018-10-31
Active, closed
AstraZeneca
Phase 3
730
Bunkyō City, Chūōku, Fukuoka, Iwakuni-shi, Kashiwa, Kōtoku, Kurume-shi, Nagoya
2018-09-27
Active, closed
AstraZeneca
Phase 3
1,246
Bunkyō City, Chūōku, Fukuoka, Hirosaki-shi, Kanazawa, Kita-gun, Koshigaya-shi, Kōtoku
2018-09-27
Recruiting
Celgene
Phase 2/3
1,541
Chiba, Sapporo, Tennoji-Ku, Shimotsuke, Chuo-ku, Minato-ku, Bunkyō City, Fukuoka
2018-07-19
Active, closed
Eli Lilly and Company
Phase 3
1,058
Asahikawa, Bunkyō, Bunkyō City, Chiyoda-ku, Chuo-ku, Sapporo-shi, Fujiidera, Fukuoka, Hamamatsu
2018-07-18
Active, closed
AstraZeneca
Phase 3
1,018
Bunkyō City, Fukuoka, Hirosaki-shi, Kanazawa, Kita-gun, Koshigaya-shi, Kōtoku, Matsuyama
2018-05-14
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,409
Asahikawa, Bunkyō City, Chiba, Chikushino-shi, Fukuoka, Gifu, Hachiōji, Hamamatsu
2018-04-13
Active, closed
Hoffmann-La Roche
Phase 2/3
1,000
Bunkyō City, Fukuoka, Hiroshima, Ishikawa, Kanagawa, Kyoto, Matsuyama, Miyagi
2017-09-22
Active, closed
AstraZeneca
Phase 3
1,186
Bunkyō City, Chūōku, Fukuoka, Hiroshima, Iwakuni-shi, Kanazawa, Kashiwa, Kōtoku
2017-06-01
Active, closed
AstraZeneca
Phase 3
953
Bunkyō City, Fukushima, Habikino-shi, Hirosaki-shi, Iizuka-shi, Iwakuni-shi, Kanazawa, Kishiwada-shi
2015-11-03
Active, closed
AstraZeneca
Phase 3
1,126
Akita, Bunkyō City, Fukuoka, Hakata-shi, Hirosaki-shi, Hiroshima, Izumo-shi, Kagoshima
2015-11-02
Active, closed
AstraZeneca
Phase 3
682
Bunkyō City, Fukuoka, Hirakata-shi, Hiroshima, Kanazawa, Kashiwa, Kitakyushu-shi, Kobe
2015-10-21
Active, closed
Eli Lilly and Company
Phase 3
453
Amagasaki, Asahikawa, Bunkyō City, Fukuoka, Habikino, Hirakata, Hiroshima, Hyōgo
2014-10-03
Active, closed
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
DrugIbrutinib
Janssen Research & Development, LLC
Phase 3
539
Bunkyō City, Hiroshima
2013-09-09
Active, closed
Washington University School of Medicine
Phase 2/3
490
Niigata, Bunkyō City
2012-12
Recruiting
Medtronic
Observational
20,000
Ageo, Bunkyō City, Gifu, Hidaka, Hiroshima, Kagoshima, Kamakura, Kawasaki
1983-01
Rows per page Showing 1–169 of 169
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/bunky-city

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 169 of those studies with a site in Bunkyō City.

How many clinical trials are recruiting in Bunkyō City?

84 of the 169 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 2 have not yet opened recruitment, 80 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Bunkyō City), 169 studies
PhaseStudiesRecruitingShare
Phase 31235572.8%
Phase 21267.1%
Phase 2/31055.9%
Phase 1/2975.3%
Phase 1864.7%
Observational432.4%
Phase 4221.2%
Not applicable100.6%

Most active sponsors

Lead sponsors with the most studies (Bunkyō City)
Lead sponsorStudiesRecruiting
AstraZeneca6129
Janssen Research & Development, LLC2611
Eli Lilly and Company2013
Alexion Pharmaceuticals, Inc.62
argenx41
Gilead Sciences40
Sanofi44
Alnylam Pharmaceuticals33
BioNTech SE33
Daiichi Sankyo32
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.